Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26430589 | 1.00 | HSD17B10 (0.50) | HSD17B10SMN1; SMN2BTKHPGDRECQL | |
| SCHEMBL24047701 | 1.00 | HSD17B10 (0.50) | HSD17B10SMN1; SMN2BTKHPGDRECQL | |
| SCHEMBL23695127 | 0.89 | HSD17B10 (0.41) | HSD17B10SMN1; SMN2HPGDRECQLCHRM2 | |
| SCHEMBL23695128 | 0.89 | HSD17B10 (0.41) | HSD17B10SMN1; SMN2HPGDRECQLCHRM2 | |
| SCHEMBL31320075 | 0.87 | SMN1; SMN2 (0.41) | HSD17B10SMN1; SMN2HPGDRECQLCHRM2 | |
| SCHEMBL17730541 | 0.87 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2BTKHPGDRECQL | |
| SCHEMBL23487150 | 0.87 | SMN1; SMN2 (0.41) | HSD17B10SMN1; SMN2HPGDRECQLCHRM2 | |
| SCHEMBL29601341 | 0.87 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2BTKHPGDRECQL | |
| SCHEMBL29785811 | 0.86 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2BTKHPGDRECQL | |
| SCHEMBL25866393 | 0.85 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2BTKCHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023184327-A1 | KINASE INHIBITORS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2023-10-05 | — | — | WO | disclosed |
| EP-3440078-B1 | HETEROCYCLIC GPR119 AGONIST COMPOUNDS | MANKIND PHARMA LTD (IN) | 2022-09-28 | — | — | EP | disclosed |
| EP-3440087-B1 | THIAZOLOPYRIDINE DERIVATIVES AS GPR119 AGONISTS | MANKIND PHARMA LTD (IN) | 2022-08-10 | — | — | EP | disclosed |
| CN-109415381-B | Thiazolopyridine derivatives as GPR119 agonists | 人类制药有限公司 | 2022-03-25 | — | — | CN | disclosed |
| US-10954229-B2 | GPR119 agonist compounds | MANKIND PHARMA LTD. (IN) | 2021-03-23 | — | — | US | disclosed |
| US-10919915-B2 | Compounds as GPR119 agonists | MANKIND PHARMA LTD. (IN) | 2021-02-16 | — | — | US | disclosed |
| US-20200317661-A1 | NOVEL GPR119 AGONIST COMPOUNDS | MANKIND PHARMA LTD. (IN) | 2020-10-08 | — | — | US | disclosed |
| US-10752622-B2 | GPR119 agonist compounds | MANKIND PHARMA LTD. (IN) | 2020-08-25 | — | — | US | disclosed |
| US-20200040006-A1 | NOVEL COMPOUNDS AS GPR119 AGONISTS | MANKIND PHARMA LTD. (IN) | 2020-02-06 | — | — | US | disclosed |
| US-20190127363-A1 | NOVEL GPR119 AGONIST COMPOUNDS | MANKIND PHARMA LTD. (IN) | 2019-05-02 | — | — | US | disclosed |
| US-5817658-A | ADMINISTERING A DIAZEPINE COMPOUND; DISEASES OF THE EAR | MERCK & COMPANY, INC. (US) | 1998-10-06 | — | — | US | disclosed |
| US-5776930-A | CARDIOVASCULAR DISORDERS | MERCK & COMPANY, INC. (US) | 1998-07-07 | — | — | US | disclosed |
| WO-1998000405-A1 | PHARMACEUTICAL PREPARATION | MERCK & CO., INC. (US) | 1998-01-08 | — | — | WO | disclosed |
| WO-1997049690-A1 | A METHOD FOR TREATING MENIERE'S DISEASE | MERCK & CO., INC. (US) | 1997-12-31 | — | — | WO | disclosed |
| US-5618830-A | TREATING INFLUENZA, PREVENTING INFECTION BY INFLUENZA VIRUS | MERCK & CO., INC. (US) | 1997-04-08 | — | — | US | disclosed |
| US-5595990-A | TREATMENT OF CARDIOVASCULAR DISORDERS | MERCK & CO., INC. (US) | 1997-01-21 | — | — | US | disclosed |
| EP-0730454-A1 | ANTIARRHYTHMIC BENZODIAZEPINES | MERCK & CO. INC. (US) | 1996-09-11 | — | — | EP | disclosed |
| US-5475109-A | Useful in prevention or treatment of infection by influenza virus | MERCK & CO., INC. (US) | 1995-12-12 | — | — | US | disclosed |
| US-5426185-A | Antiarrhythmia agents having reduced side effects | MERCK & CO., INC. (US) | 1995-06-20 | — | — | US | disclosed |
| WO-1995014471-A1 | ANTIARRHYTHMIC BENZODIAZEPINES | MERCK & CO., INC. (US) | 1995-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317661-A1 | NOVEL GPR119 AGONIST COMPOUNDS | GPR119, GPR84, GPR88 | HSD17B10 1255/4885SMN1; SMN2 2548/4885BTK 3764/4885 |
| US-20200040006-A1 | NOVEL COMPOUNDS AS GPR119 AGONISTS | GPR119, GPR84, GPR65 | HSD17B10 1274/4885SMN1; SMN2 3408/4885BTK 3829/4885 |
| US-10752622-B2 | GPR119 agonist compounds | GPR119, GPR84, GPR65 | HSD17B10 1135/4885SMN1; SMN2 2380/4885BTK 4006/4885 |
| US-10919915-B2 | Compounds as GPR119 agonists | GPR119, GPR84, GPR65 | HSD17B10 1140/4885SMN1; SMN2 3201/4885BTK 3926/4885 |
| US-10954229-B2 | GPR119 agonist compounds | GPR119, GPR84, GPR65 | HSD17B10 1135/4885SMN1; SMN2 2380/4885BTK 4006/4885 |
| US-20190127363-A1 | NOVEL GPR119 AGONIST COMPOUNDS | GPR119, GPR84, GPR88 | HSD17B10 1255/4885SMN1; SMN2 2548/4885BTK 3764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.